Clinical Application Of Imatinib Mesylate In The Treatment Of High Risk Gastrointestinal Stromal Tumors Before Operation

Objective To study the clinical efficacy of imatinib mesylate in the treatment of high-risk gastrointestinal stromal tumors before surgery.Methods The data of 73 patients with gastrointestinal stromal tumors admitted to Department of General Surgery,First Hospital of Lanzhou University from January 2014 to January 2017 were retrospectively analyzed.According to whether the patients were treated with molecular targeted drug A Imatinib sulfonate treatment was divided into control group(34)and treatment group(39).Collected and collated the control group and treatment group intraoperative,postoperative and follow-up data,and then use SPSS22.0 statistical software to analyze the clinical effect of the two groups of patients.Results 1The average operation time(101.26 ± 12.30)min,postoperative hospital stay(9.72± 1.07)days and mean postoperative hospital stay(12.91 ± 3.74)days in the treatment group were significantly higher than those in the control group(121.50 ± 18.65)min Shorten the difference between the two groups was statistically significant.2 The mean intraoperative blood loss in the treatment group was(127.87 ± 21.07)ml,and the number of intraoperative tumor rupture(1 case)was 159.97 ± 37.58 ml compared with the control group.The number of intraoperative tumor rupture(8 cases)Decreased,the difference between the two groups was statistically significant.3 The number of resected R0 tumors in the treatment group(38 cases)was larger than that of the control group(25 cases)and the difference between the two groups was statistically significant.4 The average size of resection in the treatment group was(8.99 ± 0.37)cm,while the average size of resection in the control group was(10.65 ± 2.10)cm.The treatment group was smaller than the control group,indicating that the difference between the two groups was statistically significant.5 In the treatment group,1 case had an important organ resection and 7 cases had a resection of the vital organs in the control group.The difference between the two groups was statistically significant.Conclusions In clinical work,surgical treatment is needed for patients with high or mediumrisk gastrointestinal stromal tumors.However,the effect of imatinib mesylate,a molecular targeted drug,before surgery is very obvious,Can be vigorously promoted in clinical work.